Research Study

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Principal Investigator 
David Maberley

Overview

Body Locations and Systems 
Macular Degeneration
ClinicalTrials.gov# 
NCT02307682
Status 
Closed to Recruitment
Study Start/End 
Jul 21, 2015 to Dec 29, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Theresa Wiens, Research Manager
Phone 
604-875-4111 ext.62544
Purpose of Study 

The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.